Kedudukan dalam Saham
#40870
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
Harga Saham
$0.02765
Disegerakkan terakhir: 2024-12-23
Perubahan (1 tahun)
0.00%
Perdagangan Histogen Inc. (HSTO)
Harga HSTO dengan permodalan pasaran b
Modal pasaran bagi Histogen Inc.(HSTO)
Modal Pasaran: $69.04K
Sehingga August 2026, Histogen Inc. mempunyai modal pasaran sebanyak $69.04K. Ini menjadikan Histogen Inc. syarikat ke-40870th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Histogen Inc. dari 2013 hingga 2026
HSTO berbanding dengan 5 teratas yang paling popular stocks
| Harga HSTO |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.448T
|
+7,890,461,518.54%
|
|
|
|
|
$4.457T
|
+6,454,884,178.61%
|
|
|
|
|
$4.155T
|
+6,018,026,483.06%
|
|
|
|
|
$3.697T
|
+5,354,002,319.35%
|
|
|
|
|
$2.887T
|
+4,181,340,006.50%
|
